<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347504">
  <stage>Registered</stage>
  <submitdate>19/09/2011</submitdate>
  <approvaldate>21/09/2011</approvaldate>
  <actrnumber>ACTRN12611001015932</actrnumber>
  <trial_identification>
    <studytitle>Bone mineral density of the distal femur after Total Knee Arthroplasty</studytitle>
    <scientifictitle>A comparison of bone mineral density of the distal femur following Duracon versus Interax total knee replacement in individuals with primary osteoarthrosis of the knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Knee osteoarthritis</healthcondition>
    <healthcondition>Osteopenia near knee arthroplasty implant</healthcondition>
    <healthcondition>Risk of fractures near knee arthroplasty implant</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The uncemented Duracon femoral implant has porous-coated ingrowth surface and two small fixation pegs designed to penetrate centrally into the most distal part of the medial and lateral femoral condyles. Operative surgery technique (femoral cut by guide, and insertion without cement) is the same as for the Interax prosthesis, and operation time (implant procedure) approximately 1.5 hours, as for the Interax implant. The implant is expected to be in place for at least 10-20 years after primary operation.
NB: The Duracon prosthesis has a metalbacked patella component whereas the Interax prosthesis has a cemented polyethylene patella component.</interventions>
    <comparator>The Interax femoral implant is hydroxyapatite (HA) coated with a relatively large pore size, cast mesh ingrowth surface and a central anterior placed 20 mm long fixation peg.
Operative surgery technique (femoral cut by guide, and insertion without cement) is the same as for the Duracon prosthesis, and operation time (implant procedure) approximately 1.5 hours, as for the Duracon implant. The implant is expected to be in place for at least 10-20 years after primary operation.
NB: The Duracon prosthesis has a metalbacked patella component whereas the Interax prosthesis has a cemented polyethylene patella component.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bone mineral density (BMD) adjacent to the implant. 
A Norland XR-46, Norland Corp. Fort Atkinson, Wis DEXA scanner was used.</outcome>
      <timepoint>Postoperatively (within 2 weeks), 3, 6 12 and 24 months postoperatively.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Bone mineral concentration (BMC) in the distal tibiae. 
A Norland XR-46, Norland Corp. Fort Atkinson, Wis DEXA scanner was used</outcome>
      <timepoint>Postoperatively (within 2 weeks), 3, 6 12 and 24 months postoperatively.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>HSS knee society knee score.</outcome>
      <timepoint>Preoperatively, 12 and 24 months postoperatively</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary osteoarthrosis of the knee</inclusivecriteria>
    <inclusiveminage>59</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Consuming steroid drugs (above 5mg per day).
2. Not able to participate (coorporate) due to bad mental status.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Randomization using sealed opaque envelopes</concealment>
    <sequence>Block randomization with 4 patients in each group.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/05/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Rigshospitalet, Copenhagen University Hospital, orthop. dept.</primarysponsorname>
    <primarysponsoraddress>Blegdamsvej 3
2100 Copenhagen OE</primarysponsoraddress>
    <primarysponsorcountry>Denmark</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Rigshospitalet, Copenhagen University Hospital, orthop. dept.</fundingname>
      <fundingaddress>Blegdamsvej 3
2100 Copenhagen OE</fundingaddress>
      <fundingcountry>Denmark</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Decreased periproshetic bone mineral density (BMD) after total knee arthroplasty (TKA) is well described in the literature. However, it has been predicted from Finite Element Analyse (FEM) studies that altered design of the femoral implant may have an impact on long term periprosthetic bone lose. In a randomized prospective study we followed 25 patients operated on with either a Duracon or Interax TKA to evaluate periprosthetic differences in BMD using DEXA.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Ethical Committee of Copenhagen and Frederiksberg</ethicname>
      <ethicaddress>Sjaellandsgade 40
2200 Copenhagen N</ethicaddress>
      <ethicapprovaldate>4/01/2000</ethicapprovaldate>
      <hrec>(KF) 01-261/99:</hrec>
      <ethicsubmitdate>1/11/1999</ethicsubmitdate>
      <ethiccountry>Denmark</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Matthias Therbo</name>
      <address>Rigshospitalet, Copenhagen Universty Hospital, orthop. dept. 2162, 21oo Copenhagen OE</address>
      <phone>+45 35452360</phone>
      <fax />
      <email>matthias_therbo@yahoo.dk</email>
      <country>Denmark</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Matthias Therbo</name>
      <address>Rigshospitalet, Copenhagen Universty Hospital, orthop. dept. 2162, 2100 Copenhagen OE</address>
      <phone>+45 35452360</phone>
      <fax />
      <email>matthias_therbo@yahoo.dk</email>
      <country>Denmark</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>